Application of angelica polysaccharide in preparation of medicine for treating leptospirosis

Abstract

The invention is applicable to the field of medicine, and provides application of angelica polysaccharide in preparation of a medicine for treating leptospirosis, secondary development is performed on pharmacological action of the angelica polysaccharide, and it is found that after golden hamster sensitive to leptospirosis infects leptospirosis, continuous injection is performed by adopting a standard substance of the angelica polysaccharide, so that the leptospirosis can be effectively treated. According to the application, the resistance of the golden hamster to leptospirosis can be effectively improved, the survival rate is high, the medicinal range of the angelica polysaccharide is expanded, and a basis is provided for development of new application of the angelica polysaccharide. Besides, a new thought for treating the leptospirosis is opened, the abuse of antibiotics can be effectively reduced, and the traditional Chinese medicine composition is greatly helpful for healthy development of animal husbandry.

Description

Technical Field

[0001] The invention belongs to the field of medicine, and in particular relates to an application of angelica polysaccharide in preparing a medicine for treating leptospirosis. Background Art

[0002] Leptospirosis is a zoonotic disease that spreads worldwide. It is abbreviated as leptospirosis. This infection is related to occupational or daily contact and contact with Leptospira. It is highly prevalent in flood-prone areas. The disease is particularly widespread in developing countries and tropical regions. Humans and animals are susceptible to the disease, and the clinical manifestations after infection are diverse, making it difficult to diagnose. The pathogens of leptospirosis will persist in the host body, further spread and pollute the environment, infect other people and animals, and cause serious harm. To date, veterinary clinical treatment of leptospirosis still relies on antibiotics, but the use of antibiotics can cause side effects such as disordered intestinal flora, diarrhea, and drug resistance. Therefore, exploring safer biological agents to prevent and control leptospirosis is the focus of current research.

[0003] Angelica sinensis polysaccharide (ASP) is a water-soluble heteropolysaccharide extracted, concentrated and purified from the root of Angelica sinensis, a plant of the Umbelliferae family. It is a dark brown powder with good water solubility. The main components of Angelica sinensis polysaccharide are fructose and sucrose, accounting for 40%, in addition to acidic polysaccharides with complement activity. Among them, polysaccharides in Angelica sinensis polysaccharide account for 8%, mainly including D-xylose, D-galactose, L-arabinose, glucuronic acid, galacturonic acid, etc.; it can be used as an immunostimulant or regulator, and also has anti-tumor, antioxidant, immunomodulatory, hematopoietic, liver-protective, anti-viral, radiation-proof and kidney-protective effects; but there are few reports on the treatment of Leptospira. Summary of the invention

[0004] The purpose of the present invention is to provide an application of Angelica polysaccharide in the preparation of a drug for treating leptospirosis, aiming to solve the problems raised in the background technology.

[0005] In view of the above problems, the present invention is achieved by providing an application of Angelica polysaccharide in the preparation of a drug for treating leptospirosis.

[0006] Preferably, the dosage of the Angelica polysaccharide is 40-60 mg / kg.

[0007] Preferably, the dosage of the Angelica polysaccharide is 50 mg / kg.

[0008] Another object of the present invention is to provide a drug for treating leptospirosis, comprising a pharmaceutically acceptable carrier and angelica polysaccharide as an active ingredient.

[0009] Preferably, the carrier is physiological saline.

[0010] Preferably, the concentration of the Angelica polysaccharide is 4-6 mg / mL.

[0011] Preferably, the concentration of the Angelica polysaccharide is 5 mg / mL.

[0012] The present invention conducts secondary development on the pharmacological effects of Angelica polysaccharide and finds that in golden hamsters susceptible to Leptospira, 1×10 6 / mL of leptospira, the standard product of Angelica polysaccharide is continuously injected at a certain dose, which can effectively improve the resistance of golden hamsters to leptospirosis and have a higher survival rate, expand the medicinal scope of Angelica polysaccharide, and provide a basis for the development of new uses of Angelica polysaccharide. In addition, the present invention opens up a new idea for the treatment of leptospirosis, can effectively reduce the abuse of antibiotics, and has a great help to the healthy development of animal husbandry. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] Figure 1 This is a comparison chart of the survival rates of golden hamsters in different experimental groups after being infected with Leptospira; Figure 2 The results of sampling and analysis of main organs of golden hamsters in different experimental groups after infection with Leptospira; Figure 3 This is a comparison of the load of Leptospira in various organs of golden hamsters in different experimental groups after infection with Leptospira. Figure 4 This is a comparison of the expressions of IL-1β and TNF-α in golden hamsters of different experimental groups after infection with Leptospira. DETAILED DESCRIPTION

[0014] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention.

[0015] In one embodiment of the present invention, there is provided a use of Angelica polysaccharide in the preparation of a drug for treating leptospirosis.

[0016] Specifically, the dosage of Angelica polysaccharide is 40-60 mg / kg, preferably 50 mg / kg.

[0017] In another embodiment of the present invention, a drug for treating leptospirosis is provided, comprising a pharmaceutically acceptable carrier and angelica polysaccharide as an active ingredient.

[0018] Specifically, the pharmaceutical preparation can be in the form of a liquid preparation, and the carrier can be physiological saline or the like.

[0019] In a preferred embodiment of the present invention, Angelica polysaccharide can be diluted with physiological saline, and the concentration of Angelica polysaccharide is 4-6 mg / mL, preferably 5 mg / mL.

[0020] In the embodiment of the present invention, Angelica polysaccharide (ASP) is a water-soluble heteropolysaccharide extracted, concentrated and purified from the root of Angelica sinensis, a plant of the Umbelliferae family. It is a dark brown powder with good water solubility. The present invention conducts secondary development on the pharmacological effects of Angelica polysaccharide, and finds that after golden hamsters sensitive to Leptospira are infected with Leptospira, continuous injection of Angelica polysaccharide standard products at a certain dose can effectively improve the resistance of golden hamsters to Leptospirosis, and have a higher survival rate, which expands the medicinal scope of Angelica polysaccharide and provides a basis for the development of new uses of Angelica polysaccharide. In addition, the present invention opens up a new idea for the treatment of Leptospirosis, can effectively reduce the abuse of antibiotics, and has great help for the healthy development of animal husbandry.

[0021] In order to prove the efficacy of Angelica polysaccharide, some examples are listed below to conduct verification experiments on the efficacy of Angelica polysaccharide.

[0022] Example 1: Verify the effect of Angelica polysaccharide in treating Leptospira infection Experimental drug: Angelica polysaccharide standard, Angelica polysaccharide was diluted with physiological saline at a concentration of 5 mg / mL to obtain Angelica polysaccharide standard, and injected intraperitoneally at a dose of 50 mg / kg according to the weight of golden hamsters.

[0023] Experimental methods: The experiment was divided into three groups, namely the control group, the Leptospira infection group (Leptospira group) and the Leptospira infection + Angelica polysaccharide group (Leptospira + ASP group). Ten 4-week-old male golden hamsters were selected from each group. The golden hamsters in the control group were injected with normal saline intraperitoneally; the golden hamsters in the Leptospira infection group and the Leptospira infection + Angelica polysaccharide group were injected with 56601 Leptospira intraperitoneally (10 6 / hamster). The Leptospira infection + Angelica polysaccharide group was continuously injected with Angelica polysaccharide (50 mg / kg) intraperitoneally according to the body weight after infection, while the Leptospira infection group was continuously injected with normal saline intraperitoneally. The corresponding clinical symptoms of golden hamsters infected with Leptospira were observed and the survival rate was calculated. The results are shown in Figure 1 shown.

[0024] Experimental results: The survival rate of the Leptospira infection + Angelica polysaccharide group was 90%, while all the golden hamsters in the Leptospira infection group died. This shows that Angelica polysaccharide can effectively improve the resistance of golden hamsters to Leptospira and increase the survival rate.

[0025] Example 2: Experimental drugs: Angelica polysaccharide standard product was diluted with physiological saline to a concentration of 5 mg / mL to obtain Angelica polysaccharide standard product, and injected intraperitoneally at a dose of 50 mg / kg according to the body weight of golden hamsters.

[0026] Experimental methods: The experiment was divided into three groups, namely the control group, the Leptospira infection group (Leptospira group) and the Leptospira infection + Angelica polysaccharide group (Leptospira + ASP group). Ten 4-week-old male golden hamsters were selected from each group. The golden hamsters in the control group were injected with normal saline intraperitoneally; the golden hamsters in the Leptospira infection group and the Leptospira infection + Angelica polysaccharide group were injected with 56601 Leptospira intraperitoneally (10 6 / ). The leptospira infection + angelica polysaccharide group was continuously injected with angelica polysaccharide (50 mg / kg) intraperitoneally according to the body weight after infection, while the leptospira infection group was continuously injected with normal saline intraperitoneally. The liver, kidney and lung of the golden hamsters in the leptospira infection group and the leptospira infection + angelica polysaccharide group were sampled, made into pathological sections, and then stained with HE. The results were observed under an optical microscope at 400 times. Figure 2 shown.

[0027] Experimental results: The liver, kidney and lung of the golden hamsters infected with Leptospira had different degrees of bleeding and inflammatory lesions ( Figure 2 A, B, and C are the liver, kidney, and lung of the Leptospira infection group, respectively. However, the pathological changes in the liver, kidney, and lung of the golden hamsters in the Leptospira infection + Angelica polysaccharide group were not particularly obvious, with basically no bleeding spots or inflammatory lesions ( Figure 2 D, E, and F are the liver, kidney, and lung of the Leptospira infection + Angelica polysaccharide group, respectively).

[0028] Example 3: Verify the effect of Angelica polysaccharide on the elimination of Leptospira in the body. Experimental drug: Angelica polysaccharide standard, Angelica polysaccharide was diluted with physiological saline at a concentration of 5 mg / mL to obtain Angelica polysaccharide standard, and injected intraperitoneally at a dose of 50 mg / kg according to the weight of golden hamsters.

[0029] Experimental methods: The experiment was divided into three groups, namely the control group, the Leptospira infection group (Leptospira group) and the Leptospira infection + Angelica polysaccharide group (Leptospira + ASP group). Ten 4-week-old male golden hamsters were selected from each group. The golden hamsters in the control group were injected with normal saline intraperitoneally; the golden hamsters in the Leptospira infection group and the Leptospira infection + Angelica polysaccharide group were injected with 56601 Leptospira intraperitoneally (10 6 / ). The leptospira infection + angelica polysaccharide group was continuously injected with angelica polysaccharide (50 mg / kg) intraperitoneally according to the body weight after infection, while the leptospira infection group was continuously injected with normal saline intraperitoneally. The golden hamsters in the leptospira infection group and the leptospira infection + angelica polysaccharide group were sampled, and the liver, kidney, and lung of the golden hamsters in each group were collected to extract the DNA of the leptospira in the tissues. After that, the fluorescence quantitative PCR experiment was performed to analyze the load of leptospira in each organ of the golden hamster. The results are shown in the figure. Figure 3 shown.

[0030] Experimental results: Compared with the Leptospira-infected group injected with normal saline, the Leptospira load in the liver, kidney and lung of the golden hamsters injected with Angelica polysaccharide was significantly reduced.

[0031] Example 4: Experimental drugs: Angelica polysaccharide standard product was diluted with physiological saline to a concentration of 5 mg / mL to obtain Angelica polysaccharide standard product, and injected intraperitoneally at a dose of 50 mg / kg according to the body weight of golden hamsters.

[0032] Experimental methods: The experiment was divided into three groups, namely the control group, the Leptospira infection group (Leptospira group) and the Leptospira infection + Angelica polysaccharide group (Leptospira + ASP group). Ten 4-week-old male golden hamsters were selected from each group. The golden hamsters in the control group were injected with normal saline intraperitoneally; the golden hamsters in the Leptospira infection group and the Leptospira infection + Angelica polysaccharide group were injected with 56601 Leptospira intraperitoneally (10 6 / ). The leptospira infection + angelica polysaccharide group was continuously injected with angelica polysaccharide (50 mg / kg) intraperitoneally according to the body weight after infection, while the leptospira infection group was continuously injected with normal saline intraperitoneally. The liver, kidney and lung samples of the golden hamsters in the leptospira infection group and the leptospira infection + angelica polysaccharide group were collected, and the RNA of these tissues was extracted. The fluorescence quantitative PCR method was used to determine the expression of IL-1β and TNF-α, and their expression at 2d and 4d was observed. The results are shown in Figure 4 shown.

[0033] Experimental results: On the second day after infection, the expression levels of IL-1β and TNF-α in the Leptospira infection + Angelica polysaccharide group were higher than those in the Leptospira infection group (e.g. Figure 4 On the 4th day after infection, the expression levels of IL-1β and TNF-α in the Leptospira infection + Angelica polysaccharide group were significantly lower than those in the Leptospira infection group, especially the expression of IL-1β in the liver (as shown in Figure 2A and B). Figure 4 The combined results showed that Angelica polysaccharide treatment could reduce the levels of cytokines (IL-1β and TNF-α) in organs after Leptospira infection.

[0034] In summary, in the present embodiment, when golden hamsters susceptible to Leptospira were infected with 1×10 6 After the leptospira of 100 mg / mL was detected, the standard product of Angelica polysaccharide was continuously injected at a dose of 50 mg / kg, which can effectively improve the resistance of golden hamsters to leptospirosis and achieve a survival rate of 90%. The embodiments of the present invention expand the medicinal scope of Angelica polysaccharide and provide a basis for the development of new uses of Angelica polysaccharide.

[0035] The above-mentioned embodiments only express several implementation methods of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the patent of the present invention. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.

Claims

1. Application of Angelica polysaccharide in the preparation of drugs for treating leptospirosis.

2. The use according to claim 1, characterized in that: The dosage of the Angelica polysaccharide is 40-60 mg / kg.

3. The use according to claim 2, characterized in that: The dosage of the Angelica polysaccharide is 50 mg / kg.

4. A drug for treating leptospirosis, comprising a pharmaceutically acceptable carrier, characterized in that: Angelica polysaccharide is also included as an active ingredient.

5. The drug for treating leptospirosis according to claim 4, characterized in that: The carrier is physiological saline.

6. The drug for treating leptospirosis according to claim 4 or 5, characterized in that: The concentration of the Angelica polysaccharide is 4-6 mg / mL.

7. The drug for treating leptospirosis according to claim 6, characterized in that: The concentration of the Angelica polysaccharide is 5 mg / mL.

Images